Gastric Cancer Biomarker

Gastric cancer (GC) is the fourth most common malignant disease and the second leading cause of cancer-related death worldwide. Despite significant improvements in the survival of patients with GC over the past several decades, GC is often diagnosed at an advanced stage and prognoses is still unsatisfactory due to the high incidence of recurrence. Since GC is mostly asymptomatic until it progresses to advanced stages, the early detection using effective screening approaches is important to impair GC mortalities. Biomarkers are characteristics that are objectively measured and evaluated as an indicator of normal biologic process, pathogenic processes, or pharmacological response to a therapeutic intervention. Various biomarkers related to DNA, RNA, exosome, etc. have been found by recent advances in genome analysis. Development of these biomarkers in the field of cancer treatment is expected to greatly contribute to the progress of cancer, selection of appropriate therapeutic strategies and efficient follow-up programs.

Gastric Cancer Biomarker